{"id":"NCT00586105","sponsor":"Bayer","briefTitle":"Phase III Study of Sorafenib in Patients With Renal Cell Carcinoma (RCC)","officialTitle":"A Multicenter Uncontrolled Study of Sorafenib in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-12","primaryCompletion":"2008-05","completion":"2008-05","firstPosted":"2008-01-04","resultsPosted":"2010-10-01","lastUpdate":"2014-04-16"},"enrollment":39,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Carcinoma, Renal Cell"],"interventions":[{"type":"DRUG","name":"Sorafenib (Nexavar, BAY43-9006)","otherNames":[]}],"arms":[{"label":"Sorafenib (Nexavar, BAY43-9006)","type":"EXPERIMENTAL"}],"summary":"A multicenter uncontrolled study of sorafenib in patients with unresectable and/or metastatic renal cell carcinoma (RCC) to assess the pharmacokinetic profile, safety and tolerability, and efficacy.","primaryOutcome":{"measure":"Pharmacokinetics Measured as Area Under Curve (AUC[0-12h])","timeFrame":"12 hours after at least 21 days of uninterrupted dosing","effectByArm":[{"arm":"Sorafenib (Nexavar, BAY43-9006)","deltaMin":35.5,"sd":16.1}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":20},"locations":{"siteCount":8,"countries":["China","Taiwan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":39},"commonTop":["Hand-Foot Skin Reaction","Diarrhea","Alopecia","Fatigue","Anorexia"]}}